An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects
Latest Information Update: 24 Oct 2024
At a glance
- Drugs LTI-291 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
Most Recent Events
- 08 Feb 2022 New trial record